GLYPICAN 3 targeted therapy in pediatric solid malignant tumors.

[目的]分析Glypican3作为一种新的肿瘤标志物在儿童实体恶性肿瘤诊断中的应用价值，建立新的诊断系统。最终目标是开发针对Glypican3的免疫遗传治疗。[方法]对病理材料和患者血清进行Glypican3和AFP的免疫组织化学和血清学分析。[结果]肝母细胞瘤、恶性生殖细胞瘤、肝母细胞瘤和恶性生殖细胞瘤的Glypican3免疫组织化学和血清学检测均呈阳性，三分之一的肾母细胞瘤、泡状横纹肌肉瘤和未分化肉瘤也呈阳性表达。在AFP方面，肝母细胞瘤和恶性生殖细胞瘤多为阳性。非肿瘤性疾病患者血清Glypical3水平在出生后即刻升高，随年龄增长逐渐下降。[讨论]Glypican3被确认为儿童实体恶性肿瘤的新诊断标记物。基于这项研究，对于1年以上的儿童实体恶性肿瘤难治性病例，针对Glypican3的这种新的治疗方法将是可望的。

【Purpose】The purpose of this study is to analyze the usefulness of Glypican3 as a novel diagnostic tumor marker for pediatric solid malignant tumor, and to establish the new diagnostic system. Final goal is to develop the immuno-genetic therapy targeted for the Glypican3.【Method】The immunohistochemical analysis and serological analysis of Glypican3 and AFP was performed for the pathological materials and patient’s serum. 【Results】Immunohistochemlically and serologically, most cases of hepatoblastoma and malignant germ cell tumor showed positive for Glypican3, and one of thirds Wilms tumor, alveolar type rhabdomyosarcoma and undifferentiated sarcoma were also positive. Concerning AFP, most cases of hepatoblastoma and malignant germ cell tumor showed positive. Concerning non-neoplastic patients’, serum Glypican 3 was high just after birth and gradually decreased according to their age. The level normalized by the 1 year.【Discussion】Glypican3 was confirmed as the novel diagnostic marker for pediatric solid malignant tumors. Based on this research, for the refractory cases of pediatric solid malignant tumor over 1 year, such new treatment immuno-genetic therapy targeted forGlypican 3 will be expected.